文章：

微卫星稳定或错配修复功能正常的转移性结直肠癌免疫检查点抑制剂治疗：我们是否正迈入新时代？

Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era?

原文发布日期：28 October 2023

DOI: 10.3390/cancers15215189

类型: Article

开放获取: 是

英文摘要：

Colorectal cancer (CRC) is the third most frequent cancer and the second leading cause of cancer-related deaths in Europe. About 5% of metastatic CRC (mCRC) are characterized by high microsatellite instability (MSI) due to a deficient DNA mismatch repair (dMMR), and this condition has been related to a high sensitivity to immunotherapy, in particular to the Immune Checkpoint Inhibitors (ICIs). In fact, in MSI-H or dMMR mCRC, treatment with ICIs induced remarkable response rates and prolonged survival. However, the majority of mCRC cases are mismatch-repair-proficient (pMMR) and microsatellite-stable (MSS), and unfortunately these conditions involve resistance to ICIs. This review aims to provide an overview of the strategies implemented to overcome ICI resistance and/or define subgroups of patients with MSS or dMMR mCRC who may benefit from immunotherapy.

摘要翻译： 

结直肠癌（CRC）在欧洲是第三大常见癌症，也是癌症相关死亡的第二大主要原因。约5%的转移性结直肠癌（mCRC）因DNA错配修复缺陷（dMMR）而表现为高度微卫星不稳定性（MSI），这一特征与对免疫疗法（尤其是免疫检查点抑制剂ICIs）的高敏感性相关。事实上，在MSI-H或dMMR型mCRC中，ICIs治疗能显著提高应答率并延长生存期。然而，大多数mCRC病例属于错配修复正常（pMMR）和微卫星稳定（MSS）类型，遗憾的是这些类型往往对ICIs产生耐药性。本综述旨在系统阐述当前克服ICIs耐药性的策略，并探讨如何界定可能从免疫治疗中获益的MSS或dMMR型mCRC患者亚群。

原文链接：

Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era?